Max S.
- Country
- Germany
- Department
- N/A
Research Overview
- Phase 3 Randomized Double-Blind Study of Tucidinostat and Nivolumab Versus Placebo and Nivolumab in Metastatic or Unresectable Melanoma
- Phase 3 Randomized Double-Blind Trial of Encorafenib, Binimetinib, and Pembrolizumab in BRAF V600E/K Mutation-Positive Metastatic or Unresectable Melanoma
- Phase 3 Randomized Study of IO102-IO103 and Pembrolizumab Versus Pembrolizumab Monotherapy in Untreated Unresectable or Metastatic Melanoma
Data & Insights
Has run more than one trial at 47 of 121 partner sites.
Specializations
Advanced Melanoma Treatment
The investigator specializes in treating non-ocular advanced melanoma and metastatic melanoma, with particular focus on innovative therapeutic approaches for previously treated cases.
- Unresectable melanoma management
- Advanced stage treatment strategies
- Combination therapy approaches
Their research extends to novel immunotherapy combinations and targeted treatments for advanced disease states.
Targeted Melanoma Therapy
Expertise in treating BRAF V600E/K mutation-positive melanoma and developing therapeutic strategies for locally advanced melanoma. Focus includes neoadjuvant treatment approaches and surgical interventions.
- Mutation-specific treatments
- Neoadjuvant therapy
- Surgical integration
The investigator works with both resectable and unresectable cases, implementing varied treatment modalities.
Immunotherapy Innovation
Specialized in immunotherapy combinations and novel therapeutic approaches for melanoma, including work with checkpoint inhibitors and innovative biological agents.
- Combination immunotherapy
- Treatment resistance management
- Novel therapeutic agents
Their work encompasses both first-line and subsequent treatment strategies for advanced melanoma cases.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.